![](/img/cover-not-exists.png)
Phase III randomized, placebo-controlled clinical trial evaluating the use of adjuvant endocrine therapy±everolimusin patients with high-risk, hormone receptor (HR) positive, HER2-negative breast cancer (BC): SWOG/NRG/Alliance S1207 (NCT01674140)
Chavez-Macgregor, M., Barlow, W., Pusztai, L., Rastogi, P., Ganz, P., Mamounas, E., Bandos, H., Miao, J., Gralow, J., Hortobagyi, G.Volume:
44
Language:
english
Journal:
The Breast
DOI:
10.1016/S0960-9776(19)30460-6
Date:
March, 2019
File:
PDF, 53 KB
english, 2019